Email ID
Password
Scrip   
J&J's Risperdal Consta approved for bipolar disorder in US
20 May 2009
Katie McQue

The US FDA has approved Johnson & Johnson's bi-weekly atypical antipsychotic, Risperdal Consta (risperidone) long-acting injection, as both monotherapy and adjunctive therapy to lithium and valproate, in the maintenance treatment of bipolar I disorder.

"Long-acting therapies are moving...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36